Back

Association of HbA1C with mortality and cardiovascular outcome in patients with type 2 diabetes using drugs with different hypoglycemic risk

1 September 2024 (14:00 - 14:50)
Organised by: Logo
Congress Presentation Part of: Real-world evidence on the cardiovascular effects of therapies for diabetes Antidiabetic Pharmacotherapy ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Ms Yi-Cheng Lin

Taipei Medical University Hospital, Taipei (Taiwan)

8 More presentations in this session

Presentation thumbnail
Cardiometabolic outcomes in patients with overweight and obesity undergoing weight loss trials : a network meta-analysis
Mr B. Tan (Singapore, SG)
Abstract Slides Video
Presentation thumbnail
The effect of metformin use on the risk of atrial fibrillation in patients with type 2 diabetes: data from the UK biobank
Doctor T. Guo (Xi'an, CN)
Abstract Slides Video
Presentation thumbnail
The potential protective effect of dapagliflozin on the development of cardiotoxicity in cancer patients after one year of observation.
Doctor S. Maragkoudakis (Chania, GR)
Abstract Slides Video
Presentation thumbnail
All cause mortality in people with type 2 diabetes using SGLT-2 inhibitors compared to DPP4 inhibitors using the danish registries
Doctor P. Yazdanfard (Hilleroed, DK)
Abstract Slides Video
Presentation thumbnail
Empaglifozin modifies the arterial stiffness in type-2 diabetic patients: a preliminary report.
Doctor M. Feola (Mondovi, IT)
Abstract Slides Video

Access the full session

Session thumbnail
Real-world evidence on the cardiovascular effects of therapies for diabetes

The Event

Event poster

ESC Congress 2024

1 September 2024 14:00 CET
You may be interested in
thumbnail
Congress Presentation
The impact of glycated hemoglobin A1c on cardiovascular risk in patients with and without coronary artery disease
thumbnail
Congress Presentation
Change in hbA1c following treatment with and the short-term risk of major adverse cardiovascular outcomes
thumbnail
Congress Presentation
HbA1c variability and macrovascular benefits of intensive blood pressure control in patients with type 2 diabetes

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources